Hidradenitis Suppurativa (HS) Treatment Market Size, Share, Untapped Growth Opportunities and Forecast 2033


 The global Hidradenitis Suppurativa (HS) Treatment Market is expected to surpass an impressive valuation of US$ 763.6 million in 2023 and is projected to reach US$ 1,240.9 million by 2033, growing at a CAGR of 4.97%. Hidradenitis suppurativa market is currently having vast pipeline therapies targeting interleukins, including (i.e., IL-17, IL-1), anti-TNF, JAKi, and anti-complement factor. The upcoming therapies of hidradenitis suppurativa are anticipated to come with a patient-convenient route of administration and are also expected to increase the treatment duration which will boost the market.

The growing prevalence of skin diseases is a major factor driving market expansion (UI). Also, secondary infection, obstruction of hair follicles, and inflammation of particular sweat glands all contribute to the growth of hidradenitis suppurativa. Another significant factor propelling growth of hidradenitis suppurativa market is the increasing healthcare expenditure which helps in enhacing its infrastructure. Furthermore, increasing initiatives by public and private organizations to spread awareness and increasing number of cases of obesity will expand the hidradenitis suppurativa market. Additionally, rising disposable income and changing lifestyle of people will result in the growth of hidradenitis suppurativa market. Along with this, growing geriatric population and increasing incidences of smoking will boost growth of the market.

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16512

Moreover, the market's growth is fuelled by a rise in the number of research and development activities. This will provide lucrative opportunities for the hidradenitis suppurativa market growth. In the near future, technologically sophisticated treatments such as laser operations are anticipated to fuel hidradenitis suppurativa market growth.

Furthermore, the hidradenitis suppurativa market is growing due to FDA approvals for medication delivery and clinical trials. Increasing drug approval rate and launches and growth in the number of emerging markets will further provide beneficial opportunities for the hidradenitis suppurativa market growth in the forecast period.

Key Takeaways from the Market Study

  • North America is expected to dominate the market of hidradenitis suppurativa treatment with market valuation to reach USD 620.4 million by end of the forecast period.
  • The market in East-Asia is anticipated to record fastest CAGR of 5.1% during the projected timeline.
  • By treatment type, biologics segment is expected is to lead the market with 61.4% segment share by end of 2033.
  • With market share of 65%, hospital pharmacy is expected to possess market hegemony by distribution channel, by end of the forecast period.

“Technologically sophisticated treatments like laser therapy and rapid drug approvals will fuel the market in forecast period”, comments an FMI analyst.

Competitive Landscape

The global Hidradenitis suppurativa market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. Some recent developments in this industry are as follows:

  • In June 2022, Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus were announced by Roivant and Pfizer.
  • In February 2021, AbbVie Inc., received FDA approval for HUMIRA (adalimumab), which can be used to treat moderate to severe hidradenitis suppurativa.
  • In March 2022, MoonLake had started the Phase II trial of nanobody, sonelokimab for treating moderate-to-severe hidradenitis suppurativa (HS). Sonelokimab has the potential to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that cause inflammation in the body.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global hidradenitis suppurative (HS) treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.

To understand opportunities in the Hidradentitis suppurativa treatment market, the market is segmented on the basis of Clinical stages (Hurley Stage 1-low, Hurley Stage 2-moderate, Hurley Stage 3-high) By Treatment type [(Medication- Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Zinc supplements, Pain medications), Surgery] By route of administration (Oral, tropical) By end-user (Hospitals, homecare, Specialty clinics) By distribution channel (Hospital Pharmacy, retail pharmacy, online pharmacy) By region (North America, Latin America, Europe, South-Asia, East-Asia, Oceania, Middle East, and Africa)

Key Companies Profiled

  • InflaRx N.V
  • Novartis A.G
  • Incyte Corporation
  • UCB Biopharma SPRL
  • Janssen Pharmaceuticals
  • Amgen Inc.
  • ChemoCentryx
  • Priovant Therapeutics
  • AnaptysBio
  • AbbVie Inc.
  • ACELYRIN
  • Aclaris Therapeutics Inc.

Key Segments Profiled in the Hidradenitis Suppurativa (HS) Treatment Market Industry Survey

By Clinical Stages:

  • Hurley Stage 1- Low
  • Hurley Stage 2- Moderate
  • Hurley Stage 3- High

By Treatment Type:

  • Medication
    • Biologics
    • Antibiotics
    • Hormonal Therapy
    • Immune Suppurativa Drugs
    • Zinc Supplements
    • Pain Medications
  • Surgery

By Route of Administration:

  • Oral
  • Tropical

By End Users:

  • Hospitals
  • Homecare
  • Specialty Clinics

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Comments

Post a Comment

Popular posts from this blog

Teleradiology Services Market Analysis And Demand With Forecast Overview To 2032

Image
 In 2022, it is expected that the Teleradiology Services Market would be worth around US$ 31,880.57 Million. By 2032, it is anticipated that the market for teleradiology services would reach US$5,598.3 Million. with a 19% CAGR growth forecast through 2032. The global Teleradiology Services Market is estimated to reach a market valuation of US$ 1,971.4 Million by the end of 2016 and register a CAGR of 21.0% over the forecast period (2016–2026). The growth of this market can be attributed to the favorable government initiatives regarding the adoption of teleradiology in order to provide early disease diagnosis. Besides, the application of modern-day technologies such as the adoption of cloud-based technologies, blockchain, and cryptocurrencies will lead to better efficiency and cost-effective solutions. Increasing Investments for the development of advanced solutions is augmenting the demand for the industry. Request Sample PDF Brochure: https://www.futuremarketinsights.com/reports/...
Read more

Non-Vascular Stents Market to 2032 – Global Analysis and Forecasts by Types, Technologies, Applications and End-User Verticals

Image
 The Non-Vascular Stents Market is expected to grow at a CAGR of  4.5%  over the forecast period. (2022 - 2032). The sector is expected to be valued at  US$ 1.21 billion  in 2022 and  US$ 1.9 billion by 2032. The global non-vascular stents market is expected to move forward in response to the growing demand for minimally-invasive procedures. Rising technological and material advancements are assisting in the development of specially designed stents for use in a variety of indications thereby fueling the overall non-vascular stents market growth. Non-vascular stents use small, precise incisions, resulting in scars that are smaller and less visible than those left by traditional surgical techniques, putting the patient's safety in jeopardy. The above-mentioned feature is anticipated to provide impetus to the non-vascular stents market adoption trends in coming years. Such a surgery is associated with a faster recovery period, resulting in a shorter hospital ...
Read more

From X-rays to AI: Veterinary Imaging Innovations of the Next Decade By 2022 to 2030

Image
  Between 2022 and 2030, the global veterinary imaging industry is expected to grow at a CAGR of 6.6%, from US$ 2.02 billion in 2022 to US$ 3.37 billion by 2030. A study by Future Industry Insights (FMI) predicted that by 2030, the worldwide veterinary imaging industry would bring in US$ 3.37 billion. The research study looks at the market development for veterinary imaging through 2030 in more than 20 nations. The report offers precise insights into some of the key players in the industry's crucial business strategies. According to the poll, investments are being made in the veterinary diagnostics industry as the trend towards pet humanization picks up speed. Additionally likely to fuel industry growth are governmental rules and a greater emphasis on preserving animal health. Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-12368 Growth will also be fueled by the expansion of the animal and pet care industry as a w...
Read more